© Asian Journal of Biomedical and Pharmaceutical Sciences, 2016. e Effect of the Antioxidant Drug “U-74389G” On Oviductal Congestion during Ischemia Reperfusion Injury in Rats e effect of the antioxidant drug “U-74389G” was examined, on rat model and particu- larly in an oviductal ischemia reperfusion (IR) protocol. e probable effects of that mole- cule were studied pathologically using oviductal congestion (OC) lesions. 40 rats of mean weight 231.875 g were used in the study. OC lesions were evaluated at 60 min of reperfusion (groups A and C) and at 120 min of reperfusion (groups B and D) in rats. U-74389G was administered only in groups C and D. U-74389G administration non-significantly altered the OC scores by 0 without lesions [-0.3582422 - 0.3582422] (p=0.9608). Reperfusion time non-significantly increased the OC scores by 0.2 without lesions [-0.1521699 - 0.5521699] (p= 0.2317). However, U-74389G administration and reperfusion time together signifi- cantly increased the OC scores by 0.0909091 without lesions [-0.1230462 - 0.3048644] (p=0.3951). U-74389G administration whether it interacted or not with reperfusion time failed to restore the OC lesions within short-term time context of 2 hours. Keywords: ischemia; U-74389G; fallopian tubes; oviductal congestion; reperfusion ABSTRACT : Tissue ischemia and reperfusion (IR) are among the main causes of permanent or transient damage with serious implications on adjacent organs and certainly on patients’ health. e usage of antioxidant substances as a treatment is a new concept. Furthermore, satisfactory answers have not been given yet to fundamental questions, such as, how fast does U-74389G act, when should U-74389G be administered, and at what dosage. e particularly satisfactory action of the antioxidant U-74389G in tissue protection has been noted in several performed experiments. Aſter a careful literature search was conducted, it was realized that this certain antioxidant has been tried in IR experiments. However, just few relative reports were found, not covering completely this particular matter. Also, many publications addressed trials of other similar molecules of aminosteroids (lazaroids) to which the studied molecule also belongs to. U-74389G or better 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1- piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant which prevents both arachidonic acid-induced and iron-dependent lipid peroxidation [www.caymanchem.com]. It protects against IR injury in animal heart, liver and kidney models. ese membrane- associating antioxidants are particularly effective in preventing permeability changes in brain microvascular endothelial cells monolayers [Fenglin et al., 1995]. A meta- analysis of 13 published seric variables, coming from the same experimental setting, tried to provide a numeric evaluation of U-74389G efficacy at the same endpoints (Table 1). e aim of this experimental study was to examine the effect of U-74389G on rat model and particularly in an oviductal IR protocol. e probable effects of that molecule were studied by evaluating the oviductal congestion (OC) lesions. MATERIALS AND METHODS Animal preparation is experimental study was licensed by the Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 & 14/10-1-2012 decisions. It was done at the Experimental Research Centre of ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Everything needed for the study *Corresponding author: Constantinos Tsompos Department of Obstetrics & Gynecology, Mesologi County Hospital, Etoloakarnania, Greece Email: Constantinostsompos@yahoo.com doi: 10.15272/ajbps.v6i52.765 INTRODUCTION: Received on:06/12/2015 Accepted on: 10/01/2016 Published on: 23/01/2016 QR Code for mobile Article Info: O pen A ccess Literati Research Article Constantinos Tsompos 1* , Constantinos Panoulis 2 , Konstantinos Toutouzas 3 , George Zografos 3 , Apostolos Papalois 4 1 Department of Obstetrics & Gynecology, Mesologi County Hospital, Etoloakarnania, Greece 2 Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Attiki, Greece 3 Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Greece 4 Exprerimental Research Center ELPEN Pharmaceuticals, S.A. Inc., Co., Attiki Greece Conflict of interest: Authors reported none submit your manuscript | www.jbiopharm.com